The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
2 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $3,317,824 in first-year total cost, median $1,658,912.
Most frequent study sections
- Special Emphasis Panel[ZDA1 IXN-O (04)]1
- Special Emphasis Panel[ZDA1 IXN-O (09)]1
Most frequent institutions
- C4X DISCOVERY LTD1
- ELYSIUM THERAPEUTICS, INC.1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2018 | Novel opioids that protect against oral overdose and disrupt the progression to misuse, abuse, and addiction1R01DA046102-01 | JENKINS, THOMAS E | ELYSIUM THERAPEUTICS, INC., CO | $2,841,799 | ZDA1 |
| 2018 | Preclinical development of a selective Orexin-1 receptor antagonist for treatment of cocaine addiction1R01DA043898-01A1 | FOX, CRAIG | C4X DISCOVERY LTD | $476,025 | ZDA1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.